van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard J L, Wilmotte J, Mendlewicz J
Universitair Ziekenhuis, Dienst Psychiatrie, Gent, Belgium.
Int Clin Psychopharmacol. 1995 Mar;10(1):3-9.
Two hundred hospitalized patients with DSM-III diagnosis of moderate to severe major depressive episode were randomized to receive mirtazapine or trazodone for 6 weeks in a double-blind trial. The dosages were 24-72 mg/day for mirtazapine and 150-450 mg/day for trazodone. The improvement on all depression rating scales used was generally greater for mirtazapine, with statistically significant differences over trazodone in the Hamilton Psychiatric Rating Scale for Depression total score and two subscores (the Bech melancholia factor and retardation factor), the Brief Psychiatric Rating Scale total score, the General Psychiatric Impression Global Assessment Scale, the Beck score and responder rates. Mirtazapine was well tolerated, while the trazodone-treated patients experienced somnolence more frequently, particularly during the first 2 weeks of treatment. Furthermore, postural symptoms were a clinical problem in 6% of the trazodone-treated patients. In this trial, mirtazapine showed significant clinical advantages over trazodone in terms of overall efficacy and tolerability.
在一项双盲试验中，200名被诊断为中度至重度重度抑郁发作（依据《精神疾病诊断与统计手册》第三版）的住院患者被随机分组，分别接受米氮平或曲唑酮治疗，为期6周。米氮平的剂量为每日24 - 72毫克，曲唑酮的剂量为每日150 - 450毫克。在所有使用的抑郁评定量表上，米氮平的改善情况总体上更大，在汉密尔顿抑郁量表总分及两个子量表（贝克抑郁因子和迟缓因子）、简明精神病评定量表总分、综合精神病评定量表总体评估量表、贝克评分及有效率方面，与曲唑酮相比有统计学显著差异。米氮平耐受性良好，而接受曲唑酮治疗的患者更频繁地出现嗜睡，尤其是在治疗的前两周。此外，6%接受曲唑酮治疗的患者出现体位性症状这一临床问题。在该试验中，米氮平在总体疗效和耐受性方面显示出比曲唑酮显著的临床优势。
